Glycolipid entries from the LIPID MAPS Structure Database (LMSD).
Database | Last Updated |
---|---|
ChEBI | February 3, 2022 |
KEGG | February 3, 2022 |
LIPID MAPS Structure Database | February 3, 2022 |
LipidBank | February 3, 2022 |
PubChem | February 3, 2022 |
Main Class ▲ | Sub Class | LM ID | Common Name | LipidBank ID | KEGG ID | PubChem CID | ChEBI ID | Exact Mass | Formula |
---|---|---|---|---|---|---|---|---|---|
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)
|
Isoglobotriglycosylceramide
|
GSG1331
|
||||||
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)
|
Isoglobotriglycosylceramide(d18:1/16:0)
|
1023.670569
|
C52H97NO18
|
|||||
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)
|
Isoglobotriglycosylceramide(d18:1/18:0)
|
1051.701869
|
C54H101NO18
|
|||||
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)
|
Isoglobotriglycosylceramide(d18:1/20:0)
|
1079.733169
|
C56H105NO18
|
|||||
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)
|
Isoglobotriglycosylceramide(d18:1/22:0)
|
1107.764469
|
C58H109NO18
|
|||||
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)
|
Isoglobotriglycosylceramide(d18:1/24:0)
|
1135.795769
|
C60H113NO18
|
|||||
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)
|
Isoglobotriglycosylceramide(d18:1/26:0)
|
1163.827069
|
C62H117NO18
|
|||||
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)
|
Isoglobotriglycosylceramide(d18:1/24:1(15Z))
|
1133.780119
|
C60H111NO18
|
|||||
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)
|
Isoglobotriglycosylceramide(d18:1/26:1(17Z))
|
1161.811419
|
C62H115NO18
|
|||||
Neutral glycosphingolipids
|
GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)
|
Cytolipin R
|
GSG1155
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01